Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.

Qianqian GuoXiaojie LinLingling YeRui XuYan DaiYuzhu ZhangQianjun Chen

Published in: Targeted oncology (2020)

Within the limitations of this network meta-analysis, the comparison indicates that CDK4/6is plus AIs might represent a better option for HR+ ABC as a first-line endocrine treatment compared with fulvestrant.

Keyphrases

systematic review
cell cycle
metastatic breast cancer
meta analyses
randomized controlled trial
cell proliferation
young adults
smoking cessation
breast cancer risk
childhood cancer